SR
Simon Read

Simon Read insider trades: Dianthus Therapeutics (DNTH) stock sales

Dianthus Therapeutics Last trade Aug 19, 2026 15 Form 4 filings
$631K
Sold, last 12 months
2 sales
$0
Bought, last 12 months
0 buys
9
Open-market trades
since 2019
2
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Simon reports to the SEC

Open-market buys and sales

9 trades reported on SEC Form 4, newest first

DateStockTypeValue
Aug 19, 2026DNTH↓ Sell$327K
Aug 10, 2026DNTH↓ Sell$304K
Dec 17, 2019RARX↓ Sell$471K
Nov 14, 2019RARX↓ Sell$467K
Oct 16, 2019RARX↓ Sell$469K
Sep 12, 2019RARX↓ Sell$254K
Aug 23, 2019RARX↓ Sell$278K
Jul 17, 2019RARX↓ Sell$329K
Jun 18, 2019RARX↓ Sell$222K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other DNTH insiders

Open-market trades in the last 12 months

About Simon Read's insider trades

Simon Read is an insider at Dianthus Therapeutics (DNTH). Since Jun 18, 2019, Simon has reported no open-market purchases and 9 sales worth $3.1M on SEC Form 4. In the last 12 months: 2 sales ($631K).

Their filings also include option exercises (10 filings), grants and awards (5 filings), shares returned to the company (1 filing), shares withheld for taxes (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every DNTH insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.